MedTrace Logo

Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)

NCT00354614 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2017-06-28

Study results available
· View outcomes & findings →

Summary

The primary endpoints for this study are that the AL validation will 1) achieve a sensitivity of greater than 80% for AHI values greater than or equal to 15, and 2) demonstrate a correlation coefficient of r=0.75 indicating strong correlation between the AHI of diagnostic PSG and AL.

Conditions

Interventions

DEVICE

ApneaLink Sleep Screener

Device used to evaluate for the presence of OSA

Sponsors & Collaborators

  • ResMed

    lead INDUSTRY

Principal Investigators

  • Patrick J Strollo, MD · Associate Professor of medicine and Medical Director, UPMC Sleep Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-03-31
Completion
2007-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00354614 on ClinicalTrials.gov